These results suggest the potential for timely and proactive interventions targeting modifiable risk factors, such as measuring plasma KLK1 concentrations in individuals with MetS and stroke, to mitigate stroke risk and recurrence, thereby enhancing outcomes in cerebrovascular disease management. The gene discussed is KLK1; the disease is stroke disorder.